Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RGEN 
Repligen Corporation (RGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.45% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.22B USD | Price to earnings Ratio - | 1Y Target Price 191.47 |
Price to earnings Ratio - | 1Y Target Price 191.47 | ||
Volume (30-day avg) 774981 | Beta 0.95 | 52 Weeks Range 113.50 - 182.52 | Updated Date 04/1/2025 |
52 Weeks Range 113.50 - 182.52 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.02% | Operating Margin (TTM) 4.96% |
Management Effectiveness
Return on Assets (TTM) 0.34% | Return on Equity (TTM) -1.3% |
Valuation
Trailing PE - | Forward PE 74.07 | Enterprise Value 7073234265 | Price to Sales(TTM) 11.37 |
Enterprise Value 7073234265 | Price to Sales(TTM) 11.37 | ||
Enterprise Value to Revenue 11.15 | Enterprise Value to EBITDA 88.13 | Shares Outstanding 56148600 | Shares Floating 52521921 |
Shares Outstanding 56148600 | Shares Floating 52521921 | ||
Percent Insiders 5.34 | Percent Institutions 103.39 |
Analyst Ratings
Rating 4.24 | Target Price 191.46 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Repligen Corporation
Company Overview
History and Background
Repligen Corporation was founded in 1981. Initially focused on recombinant protein A, it has evolved into a leading life sciences company providing bioprocessing technologies used in the production of biological drugs.
Core Business Areas
- Filtration: Products for tangential flow filtration (TFF) and virus filtration, used in cell culture clarification and purification.
- Chromatography: Chromatography columns and resins used for protein purification.
- Process Analytics: Process analytics and automation solutions for bioprocessing.
- Cell Culture: Cell culture growth factors and supplements that enhance cell growth in upstream bioprocessing
Leadership and Structure
The leadership team is headed by Tony J. Hunt, President and CEO. The organizational structure includes various functional departments such as R&D, Sales, Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Product Name 1: Protein A Ligands & Resins: Used for antibody purification. Holds a significant market share in this space. Revenue is a large driver for Repligen's growth. Competitors include Cytiva, Purolite, and Tosoh Bioscience.
- Product Name 2: TFF Systems: Systems and filters used for concentration and purification of biomolecules. Key for downstream processing. Market share is substantial. Competitors include Sartorius, Danaher (Pall), and Merck Millipore.
- Product Name 3: OPUSu00ae Pre-packed Columns: Chromatography columns offering ease-of-use and efficient purification. Growing in popularity. Revenue contributing more recently and has a significant growth rate. Competitors include Cytiva and Tosoh Bioscience.
Market Dynamics
Industry Overview
The bioprocessing industry is experiencing robust growth, driven by increasing demand for biologics, including monoclonal antibodies, vaccines, and gene therapies.
Positioning
Repligen is a key player in the bioprocessing market, with a strong reputation for innovative technologies and high-quality products. Its competitive advantages lie in its focused approach, strong customer relationships, and expanding product portfolio.
Total Addressable Market (TAM)
The bioprocessing market is estimated to be worth billions of dollars annually. Repligen is well-positioned to capture a significant share of this market through its innovative product offerings.
Upturn SWOT Analysis
Strengths
- Strong Brand Reputation
- Innovative Product Portfolio
- Established Customer Base
- Experienced Management Team
- High-Growth Market Segment
Weaknesses
- Reliance on Biopharmaceutical Industry
- Competition in Some Product Areas
- Potential Supply Chain Disruptions
- High Valuation (Historically)
Opportunities
- Expanding into New Geographic Markets
- Developing New Bioprocessing Technologies
- Acquiring Complementary Businesses
- Increasing Penetration in Emerging Biopharma Sectors (e.g., Cell and Gene Therapy)
Threats
- Increased Competition
- Technological Disruptions
- Changes in Regulatory Environment
- Economic Downturn
- Pricing pressures from generic biosimilars
Competitors and Market Share
Key Competitors
- DHR
- SMCI
- SYSM
Competitive Landscape
Repligen's strengths include its focused approach and innovative technologies. Its disadvantages compared to competitors include a smaller scale and more limited product portfolio compared to larger players like Danaher and Sartorius.
Major Acquisitions
ARTeSYN Biosolutions
- Year: 2020
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded Repligen's chromatography and filtration offerings.
Redsense Medical AB
- Year: 2023
- Acquisition Price (USD millions): 33
- Strategic Rationale: Expanding Repligen's existing offering through a new sensor solution.
Growth Trajectory and Initiatives
Historical Growth: Repligen has experienced strong historical growth, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued growth for Repligen, driven by the increasing demand for bioprocessing technologies. However, the expected growth rate is significantly lower than prior years.
Recent Initiatives: Recent initiatives include expanding production capacity, introducing new products, and making strategic acquisitions.
Summary
Repligen is a strong player in the bioprocessing market with innovative technologies and a solid customer base. Its growth has slowed down in recent years, requiring a renewed focus on innovation and strategic initiatives. Competition remains a key risk, as well as fluctuations in global economic environments. A well-balanced risk vs reward investment based on current market conditions.
Similar Companies
- DHR
- SMCI
- SYSM
- WAT
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Industry Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repligen Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Olivier Loeillot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1778 | Website https://www.repligen.com |
Full time employees 1778 | Website https://www.repligen.com | ||
Repligen Corporation engages in the development and commercialization of bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, scale down validation of chromatography processes, and ELISA test kits. The company also provides filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.